English
简体中文
Total: £ 56.28
Published Date: 2025-02-17 | Pages: 88 | Tables: 91 | Pharma & Healthcare
The global market for Non-Receptor Tyrosine Kinase Inhibitors was valued at US$ 8700 million in the year 2024 and is projected to reach a revised size of US$ 15790 million by 2031, growing at a CAGR of 8.9% during the forecast period.
Non-receptor tyrosine kinase inhibitors work by binding to and inhibiting the activity of these intracellular enzymes. This inhibition can prevent the phosphorylation of target proteins, disrupting the downstream signaling pathways that might otherwise lead to disease progression. These inhibitors typically block the kinase's ATP-binding site or other parts of the enzyme that are critical for its function.
North American market for Non-Receptor Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Non-Receptor Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Non-Receptor Tyrosine Kinase Inhibitors include Novartis AG, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, AstraZeneca PLC, Merck & Co., Inc., Amgen Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-Receptor Tyrosine Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Receptor Tyrosine Kinase Inhibitors.
The Non-Receptor Tyrosine Kinase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Receptor Tyrosine Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Receptor Tyrosine Kinase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novartis AG
Eli Lilly and Company
Pfizer Inc.
Johnson & Johnson
Bristol-Myers Squibb Company
AbbVie Inc.
Bayer AG
AstraZeneca PLC
Merck & Co., Inc.
Amgen Inc.
Zai Lab Limited
BeiGene
Takeda Pharmaceutical Company Limited
Segment by Type
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Segment by Application
Cancer Treatment
Autoimmune Disorders
Organ Transplantation
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-Receptor Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-Receptor Tyrosine Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Non-Receptor Tyrosine Kinase Inhibitors Market Overview
1.1 Product Definition
1.2 Non-Receptor Tyrosine Kinase Inhibitors by Type
1.2.1 Global Non-Receptor Tyrosine Kinase Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 mTOR Inhibitors
1.2.3 RAF/MEK Inhibitors
1.2.4 CDK Inhibitors
1.3 Non-Receptor Tyrosine Kinase Inhibitors by Application
1.3.1 Global Non-Receptor Tyrosine Kinase Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Cancer Treatment
1.3.3 Autoimmune Disorders
1.3.4 Organ Transplantation
1.3.5 Others
1.4 Global Non-Receptor Tyrosine Kinase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue 2020-2031
1.4.2 Global Non-Receptor Tyrosine Kinase Inhibitors Sales 2020-2031
1.4.3 Global Non-Receptor Tyrosine Kinase Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Non-Receptor Tyrosine Kinase Inhibitors Market Competition by Manufacturers
2.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Non-Receptor Tyrosine Kinase Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Non-Receptor Tyrosine Kinase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Date of Enter into This Industry
2.8 Global Non-Receptor Tyrosine Kinase Inhibitors Market Competitive Situation and Trends
2.8.1 Global Non-Receptor Tyrosine Kinase Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Non-Receptor Tyrosine Kinase Inhibitors Players Market Share by Revenue
2.8.3 Global Non-Receptor Tyrosine Kinase Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Non-Receptor Tyrosine Kinase Inhibitors Market Scenario by Region
3.1 Global Non-Receptor Tyrosine Kinase Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Region: 2020-2031
3.2.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Region: 2020-2025
3.2.2 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Region: 2026-2031
3.3 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region: 2020-2031
3.3.1 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region: 2020-2025
3.3.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region: 2026-2031
3.4 North America Non-Receptor Tyrosine Kinase Inhibitors Market Facts & Figures by Country
3.4.1 North America Non-Receptor Tyrosine Kinase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
3.4.3 North America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-Receptor Tyrosine Kinase Inhibitors Market Facts & Figures by Country
3.5.1 Europe Non-Receptor Tyrosine Kinase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
3.5.3 Europe Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-Receptor Tyrosine Kinase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Non-Receptor Tyrosine Kinase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Type (2020-2031)
4.1.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Type (2020-2025)
4.1.2 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Type (2026-2031)
4.1.3 Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Type (2020-2031)
4.2.1 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Type (2020-2025)
4.2.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Type (2026-2031)
4.2.3 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global Non-Receptor Tyrosine Kinase Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Application (2020-2031)
5.1.1 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Application (2020-2025)
5.1.2 Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Application (2026-2031)
5.1.3 Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Application (2020-2031)
5.2.1 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Application (2020-2025)
5.2.2 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Application (2026-2031)
5.2.3 Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global Non-Receptor Tyrosine Kinase Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Company Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Company Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly and Company Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Company Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Inc. Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Company Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Johnson & Johnson Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Company Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bristol-Myers Squibb Company Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 AbbVie Inc.
6.6.1 AbbVie Inc. Company Information
6.6.2 AbbVie Inc. Description and Business Overview
6.6.3 AbbVie Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AbbVie Inc. Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.6.5 AbbVie Inc. Recent Developments/Updates
6.7 Bayer AG
6.7.1 Bayer AG Company Information
6.7.2 Bayer AG Description and Business Overview
6.7.3 Bayer AG Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bayer AG Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.7.5 Bayer AG Recent Developments/Updates
6.8 AstraZeneca PLC
6.8.1 AstraZeneca PLC Company Information
6.8.2 AstraZeneca PLC Description and Business Overview
6.8.3 AstraZeneca PLC Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AstraZeneca PLC Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.8.5 AstraZeneca PLC Recent Developments/Updates
6.9 Merck & Co., Inc.
6.9.1 Merck & Co., Inc. Company Information
6.9.2 Merck & Co., Inc. Description and Business Overview
6.9.3 Merck & Co., Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Merck & Co., Inc. Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.9.5 Merck & Co., Inc. Recent Developments/Updates
6.10 Amgen Inc.
6.10.1 Amgen Inc. Company Information
6.10.2 Amgen Inc. Description and Business Overview
6.10.3 Amgen Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Amgen Inc. Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.10.5 Amgen Inc. Recent Developments/Updates
6.11 Zai Lab Limited
6.11.1 Zai Lab Limited Company Information
6.11.2 Zai Lab Limited Description and Business Overview
6.11.3 Zai Lab Limited Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Zai Lab Limited Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.11.5 Zai Lab Limited Recent Developments/Updates
6.12 BeiGene
6.12.1 BeiGene Company Information
6.12.2 BeiGene Description and Business Overview
6.12.3 BeiGene Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BeiGene Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.12.5 BeiGene Recent Developments/Updates
6.13 Takeda Pharmaceutical Company Limited
6.13.1 Takeda Pharmaceutical Company Limited Company Information
6.13.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.13.3 Takeda Pharmaceutical Company Limited Non-Receptor Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Takeda Pharmaceutical Company Limited Non-Receptor Tyrosine Kinase Inhibitors Product Portfolio
6.13.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-Receptor Tyrosine Kinase Inhibitors Industry Chain Analysis
7.2 Non-Receptor Tyrosine Kinase Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-Receptor Tyrosine Kinase Inhibitors Production Mode & Process Analysis
7.4 Non-Receptor Tyrosine Kinase Inhibitors Sales and Marketing
7.4.1 Non-Receptor Tyrosine Kinase Inhibitors Sales Channels
7.4.2 Non-Receptor Tyrosine Kinase Inhibitors Distributors
7.5 Non-Receptor Tyrosine Kinase Inhibitors Customer Analysis
8 Non-Receptor Tyrosine Kinase Inhibitors Market Dynamics
8.1 Non-Receptor Tyrosine Kinase Inhibitors Industry Trends
8.2 Non-Receptor Tyrosine Kinase Inhibitors Market Drivers
8.3 Non-Receptor Tyrosine Kinase Inhibitors Market Challenges
8.4 Non-Receptor Tyrosine Kinase Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Non-Receptor Tyrosine Kinase Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Non-Receptor Tyrosine Kinase Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Non-Receptor Tyrosine Kinase Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose) of Key Manufacturers (2020-2025)
Table 5. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Non-Receptor Tyrosine Kinase Inhibitors Average Price (US$/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Non-Receptor Tyrosine Kinase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Non-Receptor Tyrosine Kinase Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Non-Receptor Tyrosine Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Receptor Tyrosine Kinase Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Non-Receptor Tyrosine Kinase Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Region (2020-2025) & (K Dose)
Table 18. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global Non-Receptor Tyrosine Kinase Inhibitors Sales by Region (2026-2031) & (K Dose)
Table 20. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2025) & (K Dose)
Table 27. North America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2026-2031) & (K Dose)
Table 28. North America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2025) & (K Dose)
Table 32. Europe Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2026-2031) & (K Dose)
Table 33. Europe Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Sales by Region (2020-2025) & (K Dose)
Table 37. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Sales by Region (2026-2031) & (K Dose)
Table 38. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2025) & (K Dose)
Table 42. Latin America Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2026-2031) & (K Dose)
Table 43. Latin America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2020-2025) & (K Dose)
Table 47. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Sales by Country (2026-2031) & (K Dose)
Table 48. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose) by Type (2020-2025)
Table 51. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose) by Type (2026-2031)
Table 52. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Type (2020-2025)
Table 59. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Type (2026-2031)
Table 60. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose) by Application (2020-2025)
Table 61. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose) by Application (2026-2031)
Table 62. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Application (2020-2025)
Table 69. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Application (2026-2031)
Table 70. Novartis AG Company Information
Table 71. Novartis AG Description and Business Overview
Table 72. Novartis AG Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Novartis AG Non-Receptor Tyrosine Kinase Inhibitors Product
Table 74. Novartis AG Recent Developments/Updates
Table 75. Eli Lilly and Company Company Information
Table 76. Eli Lilly and Company Description and Business Overview
Table 77. Eli Lilly and Company Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. Eli Lilly and Company Non-Receptor Tyrosine Kinase Inhibitors Product
Table 79. Eli Lilly and Company Recent Developments/Updates
Table 80. Pfizer Inc. Company Information
Table 81. Pfizer Inc. Description and Business Overview
Table 82. Pfizer Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Pfizer Inc. Non-Receptor Tyrosine Kinase Inhibitors Product
Table 84. Pfizer Inc. Recent Developments/Updates
Table 85. Johnson & Johnson Company Information
Table 86. Johnson & Johnson Description and Business Overview
Table 87. Johnson & Johnson Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Johnson & Johnson Non-Receptor Tyrosine Kinase Inhibitors Product
Table 89. Johnson & Johnson Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Company Information
Table 91. Bristol-Myers Squibb Company Description and Business Overview
Table 92. Bristol-Myers Squibb Company Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Company Non-Receptor Tyrosine Kinase Inhibitors Product
Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
Table 95. AbbVie Inc. Company Information
Table 96. AbbVie Inc. Description and Business Overview
Table 97. AbbVie Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. AbbVie Inc. Non-Receptor Tyrosine Kinase Inhibitors Product
Table 99. AbbVie Inc. Recent Developments/Updates
Table 100. Bayer AG Company Information
Table 101. Bayer AG Description and Business Overview
Table 102. Bayer AG Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Bayer AG Non-Receptor Tyrosine Kinase Inhibitors Product
Table 104. Bayer AG Recent Developments/Updates
Table 105. AstraZeneca PLC Company Information
Table 106. AstraZeneca PLC Description and Business Overview
Table 107. AstraZeneca PLC Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. AstraZeneca PLC Non-Receptor Tyrosine Kinase Inhibitors Product
Table 109. AstraZeneca PLC Recent Developments/Updates
Table 110. Merck & Co., Inc. Company Information
Table 111. Merck & Co., Inc. Description and Business Overview
Table 112. Merck & Co., Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. Merck & Co., Inc. Non-Receptor Tyrosine Kinase Inhibitors Product
Table 114. Merck & Co., Inc. Recent Developments/Updates
Table 115. Amgen Inc. Company Information
Table 116. Amgen Inc. Description and Business Overview
Table 117. Amgen Inc. Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. Amgen Inc. Non-Receptor Tyrosine Kinase Inhibitors Product
Table 119. Amgen Inc. Recent Developments/Updates
Table 120. Zai Lab Limited Company Information
Table 121. Zai Lab Limited Description and Business Overview
Table 122. Zai Lab Limited Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 123. Zai Lab Limited Non-Receptor Tyrosine Kinase Inhibitors Product
Table 124. Zai Lab Limited Recent Developments/Updates
Table 125. BeiGene Company Information
Table 126. BeiGene Description and Business Overview
Table 127. BeiGene Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 128. BeiGene Non-Receptor Tyrosine Kinase Inhibitors Product
Table 129. BeiGene Recent Developments/Updates
Table 130. Takeda Pharmaceutical Company Limited Company Information
Table 131. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 132. Takeda Pharmaceutical Company Limited Non-Receptor Tyrosine Kinase Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 133. Takeda Pharmaceutical Company Limited Non-Receptor Tyrosine Kinase Inhibitors Product
Table 134. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Non-Receptor Tyrosine Kinase Inhibitors Distributors List
Table 138. Non-Receptor Tyrosine Kinase Inhibitors Customers List
Table 139. Non-Receptor Tyrosine Kinase Inhibitors Market Trends
Table 140. Non-Receptor Tyrosine Kinase Inhibitors Market Drivers
Table 141. Non-Receptor Tyrosine Kinase Inhibitors Market Challenges
Table 142. Non-Receptor Tyrosine Kinase Inhibitors Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Non-Receptor Tyrosine Kinase Inhibitors
Figure 2. Global Non-Receptor Tyrosine Kinase Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-Receptor Tyrosine Kinase Inhibitors Market Share by Type: 2024 & 2031
Figure 4. mTOR Inhibitors Product Picture
Figure 5. RAF/MEK Inhibitors Product Picture
Figure 6. CDK Inhibitors Product Picture
Figure 7. Global Non-Receptor Tyrosine Kinase Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Non-Receptor Tyrosine Kinase Inhibitors Market Share by Application: 2024 & 2031
Figure 9. Cancer Treatment
Figure 10. Autoimmune Disorders
Figure 11. Organ Transplantation
Figure 12. Others
Figure 13. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Non-Receptor Tyrosine Kinase Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 15. Global Non-Receptor Tyrosine Kinase Inhibitors Sales (2020-2031) & (K Dose)
Figure 16. Global Non-Receptor Tyrosine Kinase Inhibitors Average Price (US$/Dose) & (2020-2031)
Figure 17. Non-Receptor Tyrosine Kinase Inhibitors Report Years Considered
Figure 18. Non-Receptor Tyrosine Kinase Inhibitors Sales Share by Manufacturers in 2024
Figure 19. Global Non-Receptor Tyrosine Kinase Inhibitors Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Non-Receptor Tyrosine Kinase Inhibitors Players: Market Share by Revenue in Non-Receptor Tyrosine Kinase Inhibitors in 2024
Figure 21. Non-Receptor Tyrosine Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Non-Receptor Tyrosine Kinase Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Country (2020-2031)
Figure 24. North America Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Country (2020-2031)
Figure 25. United States Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Country (2020-2031)
Figure 28. Europe Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Country (2020-2031)
Figure 29. Germany Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Region (2020-2031)
Figure 36. China Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Country (2020-2031)
Figure 44. Latin America Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Colombia Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Non-Receptor Tyrosine Kinase Inhibitors Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Non-Receptor Tyrosine Kinase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Non-Receptor Tyrosine Kinase Inhibitors by Type (2020-2031)
Figure 55. Global Revenue Market Share of Non-Receptor Tyrosine Kinase Inhibitors by Type (2020-2031)
Figure 56. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Type (2020-2031)
Figure 57. Global Sales Market Share of Non-Receptor Tyrosine Kinase Inhibitors by Application (2020-2031)
Figure 58. Global Revenue Market Share of Non-Receptor Tyrosine Kinase Inhibitors by Application (2020-2031)
Figure 59. Global Non-Receptor Tyrosine Kinase Inhibitors Price (US$/Dose) by Application (2020-2031)
Figure 60. Non-Receptor Tyrosine Kinase Inhibitors Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
